- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.09. | Virax Biolabs Collaborating With Emory University On Clinical Studies | 1 | pulse2.com | ||
| 27.08. | Virax Biolabs (VRAX) Falls 18% on Lack of Leads | 1 | Insider Monkey | ||
| 26.08. | Virax Biolabs partners with Emory for long COVID diagnostic studies | 1 | Investing.com | ||
| 26.08. | Virax Biolabs startet mit Emory University Studien zur Long-COVID-Diagnostik | 1 | Investing.com Deutsch | ||
| 26.08. | Virax BioLabs Group Limited: Virax Biolabs Partners with Emory University on ViraxImmune Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September | 134 | PR Newswire | LONDON, Aug. 26, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on immune... ► Artikel lesen | |
| 26.08. | EXCLUSIVE: Virax Biolabs Inks Research Pact To Advance Long COVID Diagnostic Studies | 2 | Benzinga.com | ||
| VIRAX BIOLABS GROUP Aktie jetzt für 0€ handeln | |||||
| 30.07. | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 29.07. | Virax Biolabs appoints Iain Miller as independent director | 1 | Investing.com | ||
| 18.07. | Virax Biolabs receives Nasdaq letter over non-compliance with minimum bid price rule | 5 | Seeking Alpha | ||
| 18.07. | Virax Biolabs receives Nasdaq minimum bid price deficiency notice | 1 | Investing.com | ||
| 18.07. | Virax BioLabs Group Limited: Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency | 168 | PR Newswire | LONDON, July 18, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the... ► Artikel lesen | |
| 02.07. | Virax Biolabs Group Ltd - 20-F, Annual and transition report of foreign private issuers | 2 | SEC Filings | ||
| 13.06. | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 18.03. | Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes | 182 | PR Newswire | LONDON, March 18, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on... ► Artikel lesen | |
| 23.01. | Cosmos Health Inc.: Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait | 569 | ACCESS Newswire | CHICAGO, IL / ACCESS Newswire / January 23, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative... ► Artikel lesen | |
| 13.01. | Cosmos Health Inc.: Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries | 412 | ACCESS Newswire | CHICAGO, IL / ACCESSWIRE / January 13, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,95 | +0,17 % | Summit Therapeutics: Daten überzeugen - BioNTech beobachten! | Am morgigen Dienstag neigt sich die Jahrestagung der European Society for Medical Oncology (ESMO) in Berlin schon wieder dem Ende entgegen. Zahlreiche Unternehmen haben bereits am Wochenende frische... ► Artikel lesen | |
| EVOTEC | 6,972 | +1,54 % | Aktien Frankfurt: Solide Zahlen aus den USA schieben Kurse an | FRANKFURT (dpa-AFX) - Überwiegend robuste Quartalsbilanzen und Prognosen von US-Unternehmen haben dem deutschen Aktienmarkt am Dienstag etwas Anschub verliehen. Der Leitindex Dax, der sich bis zum... ► Artikel lesen | |
| ASEP MEDICAL | 6,021 | -100,00 % | Asep Medical validiert seinen Sepset(ER) Diagnosetest bei Patienten in der führenden wissenschaftlichen Fachzeitschrift Nature Communications. | 27. Mai 2025 / IRW-Press / Asep Medical Holdings Inc. ("Asep Medical" oder das "Unternehmen") (CSE: ASEP) (OTCQB: SEPSF) (FWB: JJ80) freut sich
bekanntzugeben, dass seine Tochtergesellschaft... ► Artikel lesen | |
| GINKGO BIOWORKS | 11,600 | -0,85 % | Dr. Dennis Riedl: Diese Aktie hat es in sich: Riedls Biotech-Wette auf zelluläre Landwirtschaft | ||
| AGIOS | 36,400 | -2,67 % | H.C. Wainwright reiterates Buy rating on Agios Pharma stock amid positive EMA opinion | ||
| GENPREX | 9,200 | -5,50 % | XFRA ISIN CHANGE | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenUS3724462037 Genprex Inc. 20.10.2025 US3724463027 Genprex Inc. 21.10.2025 Tausch 50:1 ► Artikel lesen | |
| PALISADE BIO | 1,725 | -2,54 % | Palisade Bio, Inc.: Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn's Disease (FSCD) | First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapies Topline safety, PK, and PD data anticipated in Q1 2026 Advances ongoing... ► Artikel lesen | |
| GEOVAX LABS | 0,567 | +5,22 % | GeoVax Labs files to sell 11.9M shares of common stock for holders | ||
| ANNOVIS BIO | 1,750 | -0,23 % | Annovis Bio Inc.: Annovis Announces Novel Biomarker Data in Alzheimer's Patients Supporting Buntanetap's Potential as a Disease-Modifying Treatment | MALVERN, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative... ► Artikel lesen | |
| HUMACYTE | 1,705 | +0,89 % | D. Boral Capital Acted as Exclusive Placement Agent to Humacyte in Connection with its $60,000,000 Registered Direct Offering | NEW YORK CITY, NEW YORK / ACCESS Newswire / October 14, 2025 / On October 7, 2025, Humacyte, Inc. (Nasdaq:HUMA), a commercial-stage biotechnology platform company developing universally implantable... ► Artikel lesen | |
| SAGIMET BIOSCIENCES | 8,050 | +2,55 % | Sagimet rises after denifanstat succeeds in late stage trial | ||
| NUVALENT | 93,39 | +2,75 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results | Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of... ► Artikel lesen | |
| QIAGEN | 42,405 | +0,32 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 66,06 | -3,25 % | Tarsus Pharmaceuticals stock price target raised to $88 from $72 at H.C. Wainwright | ||
| INHIBRX BIOSCIENCES | 57,29 | +102,01 % | Morning Market Movers: Picard Medical, Qualigen Therapeutics, Inhibrx Biosciences, MidWestOne Financial GroupSee Big Swings | BEIJING (dpa-AFX) - At 7:45 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen |
VIRAX BIOLABS GROUP LIMITED gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,585 Euro und damit -0,83 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIRAX BIOLABS GROUP LIMITED finden Sie auf Wallstreet Online.